LRPPRC and neoplasm: In the in vivo subcutaneous tumors model, ribociclib significantly reduced the tumor formation rate and average tumor volume of LRPPRC+/- cells, and the anti-tumor effect was much better than that with control cell-generated subcutaneous tumors (Fig. 2i, j).